Abstract

Melanoma is recognized as the most dangerous type of skin cancer, with high mortality and resistance to currently used treatments. To overcome the limitations of the available therapeutic options, the discovery and development of new, more effective, and safer therapies is required. In this review, the different research steps involved in the process of antimelanoma drug evaluation and selection are explored, including information regarding in silico, in vitro, and in vivo experiments, as well as clinical trial phases. Details are given about the most used cell lines and assays to perform both two- and three-dimensional in vitro screening of drug candidates towards melanoma. For in vivo studies, murine models are, undoubtedly, the most widely used for assessing the therapeutic potential of new compounds and to study the underlying mechanisms of action. Here, the main melanoma murine models are described as well as other animal species. A section is dedicated to ongoing clinical studies, demonstrating the wide interest and successful efforts devoted to melanoma therapy, in particular at advanced stages of the disease, and a final section includes some considerations regarding approval for marketing by regulatory agencies. Overall, considerable commitment is being directed to the continuous development of optimized experimental models, important for the understanding of melanoma biology and for the evaluation and validation of novel therapeutic strategies.

MeSH

Cells, Drug Discovery, Pharmaceutical Preparations, Melanoma, Therapeutics

Cited by

• Emerging Technologies for Timely Point-of-Care Diagnostics of Skin Cancer. Glob Chall, 2025
• How to Treat Melanoma? The Current Status of Innovative Nanotechnological Strategies and the Role of Minimally Invasive Approaches like PTT and PDT. Pharmaceutics, 2022
• Immunogenic cell death in cancer: concept and therapeutic implications. J Transl Med, 2023
• Exploring the application of metal-based photothermal agents in photothermal therapy combined with immune checkpoint therapy. Front Pharmacol, 2025
• Recent Advances in the Development and Utilization of Nanoparticles for the Management of Malignant Solid Tumors. Cureus, 2024
• Eph/ephrin-mediated immune modulation: a potential therapeutic target. Front Immunol, 2025
• Nanoparticles in Clinical Translation for Cancer Therapy. Int J Mol Sci, 2022
• Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer. Front Immunol, 2022
• Bioactive Bismuth Compounds: Is Their Toxicity a Barrier to Therapeutic Use? Int J Mol Sci, 2024
• Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive Mutant Advanced Melanoma. Biomedicines, 2023
• Nobiletin Induces Ferroptosis in Human Skin Melanoma Cells Through the GSK3β-Mediated Keap1/Nrf2/HO-1 Signalling Pathway. Front Genet, 2022
• The Multi-Omics Landscape and Clinical Relevance of the Immunological Signature of Phagocytosis Regulators: Implications for Risk Classification and Frontline Therapies in Skin Cutaneous Melanoma. Cancers (Basel), 2022
• Construction of immunotherapy-related prognostic gene signature and small molecule drug prediction for cutaneous melanoma. Front Oncol, 2022
• Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers (Basel), 2022
• A novel inflammatory response-related signature predicts the prognosis of cutaneous melanoma and the effect of antitumor drugs. World J Surg Oncol, 2022